Recent Updates
Recently added Catalysts

GSK2190915 milled

Phase 1

Asthma | Small molecule | Respiratory |GSK plc|Last Updated: Aug 3, 2017

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
CONTROLLEDBiomarker
Total Trials1
Total Enrollment14
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01318980A Single Dose Study to Assess the Regional Absorption and Bioavailability of 100mg GSK2190915APHASE1 COMPLETED 14Sep 30, 2010Mar 11, 2011Aug 3, 20171 United Kingdom
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Characterisation of the maximum concentration (Cmax), the time of Cmax (tmax) and Area Under the plasma concentration-time Curve (AUC) for intravenous and oral pharmacokinetics
1 month
Determination of AUC data for all routes of administration to permit calculation of relative and absolute bioavailability where appropriate.
1 month
Assessment of regiospecific bioavailability of GSK2190915A based on tmax, Cmax, and AUC to assist in subsequent oral formulation/delivery options for GSK2190915A
1 month
Secondary Endpoints
To collect further information about the safety and tolerability of GSK2190915A by assessing: physical examination, safety laboratory tests, vital signs, electrocardiogram (ECG), adverse events.
1 month
Quantitative and cumulative recovery of radiocarbon in urine and faeces to permit an assessment of deposition route for intravenous GSK2190915A.
1 month
Collection of bile to allow profiling of metabolites of GSK2190915A.
1 month
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeBASIC_SCIENCE
Treatment Arms
ArmTypeDescription
Period 1 Cohort 1 - GSK2190915 100mgEXPERIMENTALPeriod 1 - GSK2190915 100mg tablet.
Period 1 Cohort 2 - GSK2190915 100mg plus microtracerEXPERIMENTALPeriod 1 - GSK2190915 100mg tablet plus \[14C\] radiolabelled GSK2190915 microtracer solution.
Period 2 GSK2190915 100mg to proximal small bowelEXPERIMENTAL100mg of ground half 200mg GSK2190915 tablet administered to the proximal small bowel via Enterion capsule.
Period 3 GSK2190915 100 mg to distal small bowelEXPERIMENTAL100mg of ground half 200mg GSK2190915 tablet administered to the distal small bowel via Enterion capsule.
Period 4 - GSK 100mg enteric-coated tabletEXPERIMENTAL100mg enteric-coated GSK2190915 coated tablet.
Interventions
NameTypeDescription
GSK2190915 100mg milled tabletDRUGTaken orally
[14C] radiolabelled GSK2190915 solutionDRUGMicrotracer solution
GSK2190915 100mg milled tablet administered to the proximal small bowel.DRUGGround half of a 200mg tablet. Administered via Enterion capsule.
GSK2190915 100mg milled tablet administered to the distal small bowel.DRUGGround half of a 200mg tablet. Administered via Enterion capsule.
GSK2190915 100mg enteric-coated tablet.DRUGTaken orally
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 65 Years
SexFEMALE
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Healthy females as determined by an experienced study physician, based on a medical evaluation including medical history, physical examination, neurological examination, laboratory tests and electrocardiogram (ECG). A subject with a clinical abnormality or laboratory parameter...

Countries:United Kingdom
Unlock Eligibility Criteria